Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.

Abstract

This open study assessed the ability of rivastigmine to treat the neuropsychiatric complications of advanced Parkinson's disease. In a group of 12 patients, hallucinations, sleep disturbance, and carer distress were all improved and cognitive performance significantly enhanced by the drug.

• Authors: P J Reading, A K Luce, I G McKeith
• Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord) Vol. 16 Issue 6 Pg. 1171-4 (Nov 2001) ISSN: 0885-3185 [Print] United States
• PMID: 11748755 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2001 Movement Disorder Society.

Chemical References

• Carbamates
• Neuroprotective Agents
• Phenylcarbamates
• Rivastigmine

Topics

• Aged
• Carbamates (therapeutic use)
• Caregivers (psychology)
• Cognition Disorders (drug therapy, etiology)
• Female
• Follow-Up Studies
• Hallucinations (drug therapy)
• Humans
• Male
• Middle Aged
• Neuroprotective Agents (therapeutic use)
• Parkinson Disease (psychology)
• Phenylcarbamates
• Psychotic Disorders (drug therapy, etiology)
• Rivastigmine
• Stress, Psychological
• Treatment Outcome